Silence Therapeutics plc entered into Securities Purchase Agreement with certain accredited investors to issue an aggregate of 5,714,286 of its American Depositary Shares at an issue price of $21 per ADS for aggregate gross proceeds of $120,000,006 on February 2, 2024.Each ADS represents three Ordinary Shares of the Company, The closing of the Private Placement is expected to occur on February 7, 2024. The transaction will include participation from Vivo Opportunity Fund Holdings, L.P. for 595,250 ADS, 5AM Opportunities II, L.P. for 476,200 ADS, TCG Crossover Fund I, L.P. for 1,190,475 ADS, Redmile Biopharma Investments III, L.P. for 952,400 ADS, Logos Global for 976,061 ADS, Frazier Life Sciences X. L.P. for 55,836 ADS, Frazier Life Sciences XI, L.P. for 109,728 ADS, Frazier Life Sciences Public Overage Fund, L.P. for 131,445 ADS, Frazier Life Sciences Public Fund, L.P. for 274,491 ADS and Nextech Crossover I SCSP for 952,400 ADS.